Sinziana Barbu, R. Irimia, M. Popescu, Diana Preda, A. Jercan, D. Coriu, S. Badelita
{"title":"Myelomatous Meningitis - a diagnostic and therapeutic challenge","authors":"Sinziana Barbu, R. Irimia, M. Popescu, Diana Preda, A. Jercan, D. Coriu, S. Badelita","doi":"10.59854/dhrrh.2023.1.1.13","DOIUrl":null,"url":null,"abstract":"Multiple myeloma is a malignant disease, which consists of the clonal proliferation of plasma cells that will lead to the accumulation of a monoclonal protein in the serum and/or urine, with organic damage. Extramedullary involvement is found in approximately 5% of cases of myeloma. Multiple myeloma with determination in the central nervous system is extremely rare and is associated with a bad prognosis. A targeted treatment scheme for this complication is not described, but the therapeutic approach should follow the same steps as in the case of other lymphoproliferative diseases with neurological involvement ( association of intrathecal chemotherapy applications cytarabine and methotrexate, with systemic treatment and depending on the response local radiotherapy should be performed). The occurrence of extramedullary disease in the evolution of multiple myeloma is a complication associated with a poor prognosis.","PeriodicalId":425250,"journal":{"name":"Documenta Haematologica - Revista Romana de Hematologie","volume":"81 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Documenta Haematologica - Revista Romana de Hematologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.59854/dhrrh.2023.1.1.13","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Multiple myeloma is a malignant disease, which consists of the clonal proliferation of plasma cells that will lead to the accumulation of a monoclonal protein in the serum and/or urine, with organic damage. Extramedullary involvement is found in approximately 5% of cases of myeloma. Multiple myeloma with determination in the central nervous system is extremely rare and is associated with a bad prognosis. A targeted treatment scheme for this complication is not described, but the therapeutic approach should follow the same steps as in the case of other lymphoproliferative diseases with neurological involvement ( association of intrathecal chemotherapy applications cytarabine and methotrexate, with systemic treatment and depending on the response local radiotherapy should be performed). The occurrence of extramedullary disease in the evolution of multiple myeloma is a complication associated with a poor prognosis.